tolterodin pfizer 2mg retard-kapseln
pfizer pfe switzerland gmbh - tolterodinum - retard-kapseln - tolterodini-l-tartras 2 mg corresp. tolterodinum 1.37 mg, color.: e 132, excipiens pro capsula. - behandlung der hyperaktiven blase - synthetika human
tolterodin pfizer 4mg retard-kapseln
pfizer pfe switzerland gmbh - tolterodinum - retard-kapseln - tolterodini-l-tartras 4 mg corresp. tolterodinum 2.74 mg, color.: e 132, excipiens pro capsula. - behandlung der hyperaktiven blase - synthetika human
glycon comprimé
bausch health, canada inc. - chlorhydrate de metformine - comprimé - 850mg - chlorhydrate de metformine 850mg - biguanides
jamp-methotrexate solution
jamp pharma corporation - méthotrexate (méthotrexate sodique) - solution - 25mg - méthotrexate (méthotrexate sodique) 25mg - antineoplastic agents
tolterodin-mepha retard 2mg depocaps
mepha pharma ag - tolterodinum - depocaps - tolterodini l-tartras 2 mg corresp. tolterodinum 1,37 mg, color.: e 132, excipiens pro de la capsule. - traitement de la vessie hyperactive - synthetika
tolterodin-mepha retard 4mg depocaps
mepha pharma ag - tolterodinum - depocaps - tolterodini l-tartras 4 mg corresp. tolterodinum de 2,74 mg, color.: e 132, excipiens pro de la capsule. - traitement de la vessie hyperactive - synthetika
glycon comprimé
bausch health, canada inc. - chlorhydrate de metformine - comprimé - 500mg - chlorhydrate de metformine 500mg - biguanides
desfesoterodin-mepha retard 3.5 mg depotabs
mepha pharma ag - desfesoterodinum - depotabs - desfesoterodini succinas 3,5 mg corresp. desfesoterodinum 2,6 mg, color.: e 132, excipiens pro compresso obducto. - traitement de la vessie hyperactive - synthetika
desfesoterodin-mepha retard 7 mg depotabs
mepha pharma ag - desfesoterodinum - depotabs - desfesoterodini succinas 7 mg corresp. desfesoterodinum 5.2 mg, color.: e 132, excipiens pro compresso obducto. - traitement de la vessie hyperactive - synthetika
adempas
bayer ag - riociguat - hypertension pulmonaire - antihypertenseurs pour l'hypertension artérielle pulmonaire - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. l'efficacité a été démontrée dans une htap de la population, y compris les étiologies des idiopathique ou héréditaire de l'htap ou hap associée à une maladie du tissu conjonctif. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.